Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KNSA

Kiniksa Pharmaceuticals International Plc

76.06

Aug 07 • 3:59 PM ET -0.45 (-0.59%)

76.06

Aftermarket • 4:00 PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic United Kingdom Mid NASD

Peers: ALKS INDV LNTH NBIX ACAD AXSM BMRN BIIB INCY VRTX

| Held by: VTI IWM VB VBK IWO VTWO DFAS DFMC VHT DFAC

Index	RUT
Market Cap	5.93B
Enterprise Value	5.42B
Income	80.66M
Sales	840.85M
Book/sh	8.39
Cash/sh	6.74
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	366
IPO	May 24, 2018

P/E	77.34
Forward P/E	37.07
PEG	0.66
P/S	7.06
P/B	9.07
P/C	11.28
P/FCF	32.46
EV/EBITDA	53.09
EV/Sales	6.44
Quick Ratio	3.49
Current Ratio	3.90
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	0.98
EPS next Y	2.05
EPS next Q	0.36
EPS this Y	85.70%
EPS next Y	47.30%
EPS next 5Y	55.93%
EPS past 3/5Y	-34.04% -
Sales past 3/5Y	45.45% -
EPS Y/Y TTM	1646.61%
Sales Y/Y TTM	58.85%
EPS Q/Q	33.30%
Sales Q/Q	55.36%
Earnings	Jul 28 BMO
EPS/Sales Surpr.	0.17% 7.56%

Insider Own	42.08%
Insider Trans	-2.14%
Inst Own	61.86%
Inst Trans	6.25%
ROA	10.36%
ROE	14.04%
ROIC	12.24%
Gross Margin	54.45%
Oper. Margin	11.92%
Profit Margin	9.59%
SMA20	10.18%
SMA50	24.51%
SMA200	55.51%
Trades

Shs Outstand	48.24M
Shs Float	45.19M
Short Float	9.98%
Short Ratio	5.93
Short Interest	4.51M
52W High	82.94 -8.30%
52W Low	31.78 139.33%
Volatility	4.74% 4.96%
ATR (14)	3.49
RSI (14)	63.28
Beta	0.08
Rel Volume	0.29
Avg Volume	760.86K
Volume	217,882

Perf Week	2.31%
Perf Month	16.34%
Perf Quarter	33.60%
Perf Half Y	78.63%
Perf YTD	84.39%
Perf Year	129.72%
Perf 3Y	322.32%
Perf 5Y	479.28%
Perf 10Y	-
Recom	1.00
Target Price	98.00
Prev Close	76.51
Price	76.06
Change %	-0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-19-26	Initiated	Canaccord Genuity	Buy	$62
Sep-29-25	Initiated	TD Cowen	Buy	$60
Mar-13-25	Initiated	Citigroup	Buy	$40
Sep-13-24	Initiated	Jefferies	Buy	$40
May-03-24	Initiated	Wells Fargo	Overweight	$34
Jun-29-20	Reiterated	BofA Securities	Buy	$25 → $40
Apr-01-20	Initiated	BofA/Merrill	Buy	$25
Mar-11-19	Initiated	Barclays	Overweight	$26
Dec-12-18	Reiterated	Wedbush	Outperform	$31 → $33
Jun-19-18	Initiated	JMP Securities	Mkt Outperform	$33

Jul-28-26 03:21PM	Kiniksa Pharmaceuticals, Ltd. Q2 2026 Earnings Call Summary (Moby) +25.03%
10:09AM	Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance (InvestorsHub)
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-27-26 09:23AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2026: Everything You Need To Know Ahead Of ... (GuruFocus.com)
Jul-23-26 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 (GlobeNewswire)
03:14PM	Loading…
Jun-23-26 03:14PM	Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View (Investor's Business Daily)
03:03PM	Biotech Kiniska Pushes Toward A Buy Zone With Blockbuster Drug Sales In View (Investor's Business Daily)
May-29-26 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Apr-29-26 03:05AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ... (GuruFocus.com)
Apr-28-26 07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution (GlobeNewswire) +23.48%
Apr-23-26 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 (GlobeNewswire)
Apr-08-26 08:00AM	Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST (rilonacept) in Recurrent Pericarditis (GlobeNewswire)
Apr-06-26 04:27PM	Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market (Investor's Business Daily)
Mar-04-26 01:35PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily)
Feb-26-26 08:37AM	Kiniksa price target raised to $53 from $50 at Wedbush (TipRanks)
08:17PM	Loading…
Feb-25-26 08:17PM	Nurix Therapeutics Stock Sees RS Rating Jump To 82 (Investor's Business Daily)
04:01PM	Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-24-26 08:06PM	Kiniksa Pharmaceuticals, Ltd. Q4 2025 Earnings Call Summary (Moby) -8.21%
04:01PM	Kiniksa Pharmaceuticals International PLC (KNSA) Q4 2025 Earnings Call Highlights: Record ... (GuruFocus.com)
12:49PM	Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Feb-23-26 04:48PM	Do Options Traders Know Something About KNSA Stock We Don't? (Zacks)
07:20AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-19-26 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
10:00AM	Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:40AM	Shopify, eBay upgraded: Wall Street's top analyst calls (The Fly)
Feb-17-26 10:00AM	Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-12-26 07:30AM	Kiniksa Pharmaceuticals Provides Corporate Update (GlobeNewswire)
Jan-07-26 04:01PM	Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
06:50AM	Loading…
Dec-22-25 06:50AM	Why Analysts Favor Kiniksa Pharmaceuticals (KNSA) (Insider Monkey)
Nov-12-25 04:01PM	Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-30-25 08:25AM	New Strong Sell Stocks for Oct. 30th (Zacks)
Oct-28-25 08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-27-25 09:28AM	Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KNSA) Reports Q3 2025 Result (GuruFocus.com)
Oct-23-25 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 (GlobeNewswire)
Oct-17-25 08:00AM	Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis (GlobeNewswire)
Oct-16-25 12:10PM	Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again (Zacks)
Oct-14-25 09:55AM	Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet (Zacks)
Oct-06-25 09:50AM	GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal (Zacks)
08:50AM	Here's What Could Help Kiniksa Pharmaceuticals International, plc (KNSA) Maintain Its Recent Price Strength (Zacks)
Sep-29-25 08:06AM	Beat the Market the Zacks Way: Helios Technologies, InterDigital, UnitedHealth in Focus (Zacks) +6.25%
Sep-26-25 10:05AM	CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program (Zacks)
Sep-25-25 11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 11:06AM	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug (Zacks)
04:47AM	Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience (Zacks)
Sep-23-25 09:23AM	5 Biotech Stocks Worth Adding to Your Portfolio Now (Zacks)
Sep-22-25 12:03PM	SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU (Zacks)
11:29AM	FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing (Zacks)
Sep-19-25 08:50AM	Kiniksa Pharmaceuticals International, plc (KNSA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Sep-15-25 09:52AM	Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain (Zacks)
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
Sep-04-25 11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 10:02AM	Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results (Zacks)
09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why (Zacks)
Sep-02-25 09:02AM	Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA? (Zacks)
Sep-01-25 10:50AM	ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win (Zacks)
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks)
Aug-28-25 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 11:16AM	Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin (Zacks)
Aug-25-25 11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
Aug-18-25 09:55AM	Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade (Zacks)
08:50AM	Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Aug-14-25 09:08AM	Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas (Zacks)
Aug-13-25 12:31PM	Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
07:39AM	5 Stocks With Recent Price Strength Amid Trade & Rate Cut Uncertainties (Zacks)
Aug-05-25 12:00PM	Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know (Zacks)
Aug-01-25 01:32PM	Just The Tonic: This Medical Stock, A Mutual Fund Darling, Tests Entry Amid 58% Run (Investor's Business Daily) +5.68%
12:20PM	Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge (Zacks)
09:55AM	Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect? (Zacks)
08:50AM	Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going (Zacks)
Jul-30-25 03:11AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... (GuruFocus.com)
Jul-29-25 08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates (Zacks) +12.32%
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-28-25 09:29AM	Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KNSA) Reports Q2 2025 Result (GuruFocus.com)
Jul-24-25 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire)
Jul-03-25 08:42AM	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore (Zacks)
Jul-02-25 07:00PM	Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth (Motley Fool)
09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 01:38PM	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind (Investor's Business Daily)
01:37PM	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind (Investor's Business Daily)
Jun-05-25 07:00AM	Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis (GlobeNewswire)
May-29-25 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-05-25 04:51PM	Kiniksa Pharmaceuticals: Making Steady Progress (Seeking Alpha)
Apr-30-25 08:30AM	Kiniksa Pharmaceuticals Announces GRAMMY Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis (GlobeNewswire)
Apr-29-25 03:07PM	Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript (Seeking Alpha) +20.54%
08:35AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
02:10AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everything You Need To Know Ahead Of ... (GuruFocus.com)
02:10AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-24-25 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 (GlobeNewswire)
Apr-22-25 07:21AM	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
Apr-21-25 09:54AM	uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? (Zacks)
Apr-10-25 09:31AM	Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks) -6.28%

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

CEO & Chairman of the BoardMr. Sanjiv K. Patel

Executive VP & CFOMr. Mark A. Ragosa C.F.A.

Executive VPMr. Ross Michael Moat

M.D.Dr. John F. Paolini FACC

ConsultantMr. Eben Tessari

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cole G Bradley	Director	Jul 29 '26	Sale	81.43	3,673	299,092	11,672	Jul 31 04:34 PM
Tessari Eben	Former Affiliate	Jul 29 '26	Proposed Sale	79.74	67,062	5,347,344		Jul 29 04:03 PM
Cole G Bradley	Director	Jul 29 '26	Proposed Sale	81.43	3,673	299,092		Jul 29 04:02 PM
Paolini John F.	CHIEF MEDICAL OFFICER	May 01 '26	Option Exercise	10.36	58,424	605,273	124,047	May 05 04:54 PM
Paolini John F.	CHIEF MEDICAL OFFICER	May 01 '26	Sale	53.71	58,424	3,137,823	65,623	May 05 04:54 PM
Paolini John F.	Officer	May 01 '26	Proposed Sale	53.71	58,424	3,137,710		May 01 04:45 PM
Patel Sanj K	CHAIRMAN & CEO	May 01 '26	Option Exercise	30.93	48,565	1,502,115	48,565	May 01 04:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 01 '26	Sale	54.02	48,565	2,623,481	0	May 01 04:32 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 28 '26	Option Exercise	12.56	483,654	6,075,153	483,654	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 29 '26	Option Exercise	30.93	22,544	697,286	22,544	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 30 '26	Option Exercise	30.93	2,141	66,221	2,141	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 28 '26	Sale	51.86	483,654	25,081,991	0	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 29 '26	Sale	54.01	22,544	1,217,601	0	Apr 30 06:33 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 30 '26	Sale	54.01	2,141	115,635	0	Apr 30 06:33 PM
Quart Barry D	Director	Apr 28 '26	Option Exercise	14.33	13,099	187,709	25,645	Apr 29 04:46 PM
Quart Barry D	Director	Apr 28 '26	Sale	50.10	13,099	656,260	12,546	Apr 29 04:46 PM
Patel Sanj K	Officer	Apr 28 '26	Proposed Sale	51.60	344,591	17,780,309		Apr 28 04:49 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Apr 09 '26	Sale	46.69	6,625	309,321	27,418	Apr 13 04:35 PM
Moat Ross	CHIEF OPERATING OFFICER	Apr 09 '26	Sale	46.69	1,703	79,513	12,029	Apr 13 04:34 PM
Moat Ross	Officer	Apr 09 '26	Proposed Sale	46.69	1,703	79,513		Apr 09 04:03 PM
Megna Michael R	Officer	Apr 09 '26	Proposed Sale	46.69	6,625	309,321		Apr 09 04:02 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 06 '26	Option Exercise	10.36	7,278	75,400	7,278	Apr 08 04:43 PM
Patel Sanj K	CHAIRMAN & CEO	Apr 06 '26	Sale	50.01	7,278	363,973	0	Apr 08 04:43 PM
Moat Ross	CHIEF OPERATING OFFICER	Apr 06 '26	Sale	48.58	2,367	114,989	12,029	Apr 08 04:39 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Apr 07 '26	Option Exercise	1.00	3,932	3,932	35,709	Apr 08 04:38 PM
Quart Barry D	Director	Apr 06 '26	Option Exercise	14.33	6,901	98,891	19,447	Apr 08 04:34 PM
Quart Barry D	Director	Apr 06 '26	Sale	50.00	6,901	345,050	12,546	Apr 08 04:34 PM
Quart Barry D	Director	Apr 06 '26	Proposed Sale	50.00	20,000	1,000,000		Apr 06 04:55 PM
Patel Sanj K	Officer	Apr 06 '26	Proposed Sale	50.00	219,591	10,979,550		Apr 06 04:54 PM
Moat Ross	Officer	Apr 06 '26	Proposed Sale	48.58	2,367	114,989		Apr 06 04:04 PM
Ragosa Mark	Officer	Mar 09 '26	Proposed Sale	45.92	36,722	1,686,179		Mar 09 05:24 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Mar 02 '26	Option Exercise	10.36	40,000	414,400	101,324	Mar 04 04:40 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Mar 02 '26	Sale	44.82	40,000	1,792,940	61,324	Mar 04 04:40 PM
Paolini John F.	Officer	Mar 02 '26	Proposed Sale	44.82	40,000	1,792,970		Mar 02 05:22 PM
Quart Barry D	Director	Feb 12 '26	Option Exercise	15.47	2,690	41,614	15,236	Feb 12 04:34 PM
Quart Barry D	Director	Feb 10 '26	Option Exercise	15.47	110	1,702	12,656	Feb 12 04:34 PM
Quart Barry D	Director	Feb 12 '26	Sale	45.00	2,690	121,050	12,546	Feb 12 04:34 PM
Quart Barry D	Director	Feb 10 '26	Sale	45.00	110	4,950	12,546	Feb 12 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Feb 09 '26	Option Exercise	13.87	10,845	150,371	29,931	Feb 11 04:38 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Feb 09 '26	Sale	43.28	17,845	772,254	12,086	Feb 11 04:38 PM
Quart Barry D	Director	Feb 03 '26	Option Exercise	15.47	12,528	193,808	25,074	Feb 04 06:24 PM
Quart Barry D	Director	Feb 04 '26	Option Exercise	15.47	2,602	40,253	15,148	Feb 04 06:24 PM
Quart Barry D	Director	Feb 02 '26	Option Exercise	15.47	830	12,840	13,376	Feb 04 06:24 PM
Quart Barry D	Director	Feb 03 '26	Sale	45.27	12,528	567,143	12,546	Feb 04 06:24 PM
Quart Barry D	Director	Feb 04 '26	Sale	45.02	2,602	117,142	12,546	Feb 04 06:24 PM
Quart Barry D	Director	Feb 02 '26	Sale	45.00	830	37,350	12,546	Feb 04 06:24 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jan 08 '26	Sale	41.89	12,000	502,680	19,086	Jan 09 04:35 PM
Quart Barry D	Director	Dec 15 '25	Option Exercise	10.36	20,129	208,536	32,675	Dec 17 04:38 PM
Quart Barry D	Director	Dec 15 '25	Sale	41.51	20,129	835,555	12,546	Dec 17 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Dec 15 '25	Option Exercise	8.83	6,000	52,980	28,714	Dec 17 04:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	Dec 15 '25	Sale	41.56	12,048	500,715	16,666	Dec 17 04:37 PM
Quart Barry D	Director	Dec 15 '25	Proposed Sale	41.51	58,889	2,444,530		Dec 15 05:13 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 08 '25	Option Exercise	11.34	42,841	486,025	73,927	Dec 10 05:06 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 08 '25	Sale	41.49	42,841	1,777,473	31,086	Dec 10 05:06 PM
Ragosa Mark	Officer	Dec 08 '25	Proposed Sale	41.49	72,686	3,015,917		Dec 08 05:06 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 26 '25	Option Exercise	22.89	200	4,578	22,914	Dec 01 04:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 26 '25	Sale	42.89	200	8,578	22,714	Dec 01 04:37 PM
Tessari Eben	Officer	Nov 26 '25	Proposed Sale	42.89	48,384	2,075,190		Nov 26 05:24 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 17 '25	Option Exercise	8.83	6,500	57,395	35,184	Nov 19 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 17 '25	Sale	41.24	12,470	514,224	22,714	Nov 19 04:38 PM
Tessari Eben	Officer	Nov 17 '25	Proposed Sale	41.24	12,470	514,225		Nov 17 05:07 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Nov 12 '25	Option Exercise	30.93	19,900	615,507	50,986	Nov 14 04:35 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Nov 12 '25	Sale	40.94	19,900	814,706	31,086	Nov 14 04:35 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Oct 31 '25	Option Exercise	6.60	82,542	545,040	143,866	Nov 04 04:36 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Oct 31 '25	Sale	37.14	82,542	3,065,610	61,324	Nov 04 04:36 PM
Paolini John F.	Officer	Oct 31 '25	Proposed Sale	37.14	82,542	3,065,800		Oct 31 05:15 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Oct 28 '25	Option Exercise	30.93	100	3,093	31,186	Oct 30 04:47 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Oct 28 '25	Sale	41.00	100	4,100	31,086	Oct 30 04:47 PM
Ragosa Mark	Officer	Oct 28 '25	Proposed Sale	41.00	20,000	820,000		Oct 28 04:54 PM
Ragosa Mark	Officer	Oct 28 '25	Proposed Sale	41.00	20,000	820,000		Oct 28 04:52 PM
Patel Sanj K	CHAIRMAN & CEO	Oct 20 '25	Option Exercise	3.80	121,248	460,742	233,042	Oct 22 05:09 PM
Patel Sanj K	CHAIRMAN & CEO	Oct 22 '25	Option Exercise	3.80	97,390	370,082	209,184	Oct 22 05:09 PM
Patel Sanj K	CHAIRMAN & CEO	Oct 21 '25	Option Exercise	3.80	39,331	149,458	151,125	Oct 22 05:09 PM
Patel Sanj K	CHAIRMAN & CEO	Oct 20 '25	Sale	38.90	121,248	4,717,015	111,794	Oct 22 05:09 PM
Patel Sanj K	CHAIRMAN & CEO	Oct 22 '25	Sale	38.83	97,390	3,781,654	111,794	Oct 22 05:09 PM
Patel Sanj K	CHAIRMAN & CEO	Oct 21 '25	Sale	38.77	39,331	1,524,863	111,794	Oct 22 05:09 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Oct 20 '25	Option Exercise	11.59	39,435	456,999	77,536	Oct 22 05:06 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Oct 20 '25	Sale	38.87	50,490	1,962,781	27,046	Oct 22 05:06 PM
Patel Sanj K	Officer	Oct 20 '25	Proposed Sale	38.90	257,969	10,035,561		Oct 20 05:49 PM
Megna Michael R	Officer	Oct 20 '25	Proposed Sale	38.88	50,490	1,962,914		Oct 20 05:48 PM
Tessari Eben	CHIEF OPERATING OFFICER	Oct 14 '25	Option Exercise	8.83	6,500	57,395	41,052	Oct 16 04:35 PM
Tessari Eben	CHIEF OPERATING OFFICER	Oct 14 '25	Sale	37.67	12,368	465,843	28,684	Oct 16 04:35 PM
Tessari Eben	Officer	Oct 14 '25	Proposed Sale	37.66	12,368	465,786		Oct 14 04:52 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 29 '25	Option Exercise	17.92	42,000	752,640	76,552	Oct 01 04:44 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 29 '25	Sale	38.33	42,000	1,609,860	34,552	Oct 01 04:44 PM
Tessari Eben	Officer	Sep 29 '25	Proposed Sale	38.33	42,000	1,609,716		Sep 29 05:24 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 15 '25	Option Exercise	8.83	6,500	57,395	50,952	Sep 17 04:45 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 15 '25	Sale	36.46	16,400	597,976	34,552	Sep 17 04:45 PM
Tessari Eben	Officer	Sep 15 '25	Proposed Sale	36.46	16,400	598,016		Sep 15 05:20 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 04 '25	Option Exercise	15.51	85,271	1,322,631	129,723	Sep 08 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 05 '25	Option Exercise	15.52	13,389	207,797	57,841	Sep 08 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 04 '25	Sale	35.52	85,271	3,028,826	44,452	Sep 08 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 05 '25	Sale	35.66	13,389	477,452	44,452	Sep 08 04:38 PM
Moat Ross	CHIEF CORP. & COMM. OFFICER	Sep 04 '25	Sale	35.31	3,523	124,397	9,415	Sep 08 04:37 PM
Tessari Eben	Officer	Sep 05 '25	Proposed Sale	35.66	13,389	477,497		Sep 05 04:39 PM
Tessari Eben	Officer	Sep 04 '25	Proposed Sale	35.52	85,271	3,028,740		Sep 04 04:52 PM
Moat Ross	Officer	Sep 04 '25	Proposed Sale	35.31	3,523	124,397		Sep 04 04:51 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 03 '25	Option Exercise	15.50	15,091	233,912	59,543	Sep 03 05:31 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 03 '25	Sale	35.50	15,091	535,730	44,452	Sep 03 05:31 PM
Tessari Eben	Officer	Sep 03 '25	Proposed Sale	35.50	15,091	535,778		Sep 03 04:56 PM

Open in Screener

CSTL

Castle Biosciences Inc

32.03

Aug 07 • 3:59 PM ET +1.56 (5.12%)

32.03

Aftermarket • 4:00 PM ET 0.00 (0.00%)

Healthcare Diagnostics & Research USA Small NASD

CSTL Castle Biosciences Inc daily Stock Chart

Peers: VCYT WGS NTRA GH DGX LH A DHR TMO OPK

| Held by: IWM VTI IWN VXF IBB BSVO SCHA VTWO DFMC XHS

Index	RUT
Market Cap	978.50M
Enterprise Value	748.34M
Income	-19.41M
Sales	357.28M
Book/sh	15.41
Cash/sh	8.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	883
IPO	Jul 25, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	2.74
P/B	2.08
P/C	3.67
P/FCF	-
EV/EBITDA	-
EV/Sales	2.09
Quick Ratio	5.85
Current Ratio	6.04
Debt/Eq	0.08
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	-0.65
EPS next Y	-0.99
EPS next Q	-0.36
EPS this Y	-53.28%
EPS next Y	22.27%
EPS next 5Y	21.60%
EPS past 3/5Y	31.36% -8.93%
Sales past 3/5Y	35.94% 40.60%
EPS Y/Y TTM	-100.37%
Sales Y/Y TTM	3.18%
EPS Q/Q	-144.28%
Sales Q/Q	20.14%
Earnings	Jul 30 AMC
EPS/Sales Surpr.	82.80% 20.07%

Insider Own	2.55%
Insider Trans	-29.07%
Inst Own	89.73%
Inst Trans	-0.98%
ROA	-3.51%
ROE	-4.20%
ROIC	-3.86%
Gross Margin	74.13%
Oper. Margin	-8.99%
Profit Margin	-5.43%
SMA20	22.27%
SMA50	35.02%
SMA200	10.17%
Trades

Shs Outstand	30.51M
Shs Float	29.77M
Short Float	4.78%
Short Ratio	3.15
Short Interest	1.42M
52W High	44.28 -27.66%
52W Low	17.72 80.74%
Volatility	7.37% 5.68%
ATR (14)	1.51
RSI (14)	77.37
Beta	0.98
Rel Volume	0.53
Avg Volume	450.80K
Volume	241,133

Perf Week	14.39%
Perf Month	30.42%
Perf Quarter	66.48%
Perf Half Y	-1.14%
Perf YTD	-17.66%
Perf Year	63.00%
Perf 3Y	79.04%
Perf 5Y	-55.40%
Perf 10Y	-
Recom	1.11
Target Price	44.00
Prev Close	30.47
Price	32.03
Change %	5.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-25-26	Initiated	Roth Capital	Buy	$40
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

Show Previous Ratings

Aug-03-26 10:55AM	Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (IPO-Edge.com) +8.54%
Jul-31-26 08:30AM	Castle Biosciences, Inc. Q2 2026 Earnings Call Summary (Moby)
01:03AM	Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ... (GuruFocus.com)
Jul-30-26 04:05PM	Castle Biosciences Reports Second Quarter 2026 Results (PR Newswire) +9.53%
Jul-22-26 07:00AM	Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference (PR Newswire)
04:30PM	Loading…
Jul-14-26 04:30PM	Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test (PR Newswire)
Jul-09-26 07:00AM	Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 (PR Newswire)
Jul-01-26 05:41PM	SkylineDxs Merlin CP-GEP Granted FDA Breakthrough Device Designation (Exec Edge)
Jun-25-26 04:30PM	DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy (PR Newswire) +6.07%
Jun-23-26 07:00AM	Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal (PR Newswire)
Jun-19-26 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-16-26 07:00AM	Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus (PR Newswire)
May-13-26 07:00AM	Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference (PR Newswire)
May-12-26 07:00AM	Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation (PR Newswire)
May-06-26 08:22PM	Castle Biosciences, Inc. Q1 2026 Earnings Call Summary (Moby) -22.26%
04:05PM	Loading…
04:05PM	Castle Biosciences Reports First Quarter 2026 Results (PR Newswire)
May-05-26 07:00AM	Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month (PR Newswire)
May-04-26 07:00AM	New Data at DDW 2026 Show TissueCypher Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus (PR Newswire)
Apr-21-26 07:00AM	Castle Biosciences to Present New Data Demonstrating DecisionDx-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS (PR Newswire)
Apr-15-26 07:00AM	Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 (PR Newswire)
Apr-10-26 07:00AM	Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year (PR Newswire)
Mar-27-26 09:05AM	Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 (PR Newswire)
Mar-13-26 11:02AM	Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB (GlobeNewswire)
Mar-09-26 07:00AM	DecisionDx-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk (GlobeNewswire)
Mar-04-26 04:30PM	Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB (GlobeNewswire)
Mar-03-26 04:30PM	Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas (GlobeNewswire)
Mar-02-26 11:43AM	LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata (Zacks) -5.34%
09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
Feb-27-26 12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks) -7.25%
12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks)
12:08PM	Loading…
12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
12:06PM	PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View (Zacks)
11:14AM	Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline (Zacks)
09:49AM	Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
08:30AM	Castle Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:06AM	Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
Feb-26-26 06:00PM	Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
05:48PM	Castle Biosciences Q4 Earnings Call Highlights (MarketBeat)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks)
11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
10:54AM	ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance (Zacks)
10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks)
10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks)
10:08AM	Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:52AM	ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
09:21AM	Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss (Zacks)
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
10:56AM	JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations (Zacks)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:55AM	Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y (Zacks)
Feb-24-26 12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Feb-23-26 11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks)
10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-20-26 10:20AM	Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View (Zacks) -6.80%
09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
Feb-19-26 05:46PM	Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire) -6.92%
11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
10:00AM	Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Feb-13-26 12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-11-26 10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
10:22AM	Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
09:35AM	Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-06-26 11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.32%
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:31AM	AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
07:00AM	Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 (GlobeNewswire)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks) -10.22%
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool)
11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
08:30AM	CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Jan-30-26 08:47AM	Viking Therapeutics to Report Q4 Earnings: Here's What to Know (Zacks)

Castle Biosciences, Inc. is a molecular diagnostics company, which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

FounderMr. Derek J. Maetzold

CFO & TreasurerMr. Frank Stokes

Chief Operating OfficerMs. Kristen M. Oelschlager R.N.

Chief Commercial OfficerMr. Tobin W. Juvenal

Vice President of Investor Relations & Corporate AffairsMs. Camilla Zuckero

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Juvenal Tobin W	Chief Commercial Officer	Nov 24 '25	Sale	38.39	1,301	49,945	77,694	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 04 '26	Option Exercise	2.39	20,356	48,651	41,835	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 05 '26	Option Exercise	2.39	2,546	6,085	24,025	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 04 '26	Sale	31.11	20,356	633,261	21,479	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 04 '26	Sale	31.11	15,085	469,284	20,080	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 05 '26	Sale	30.68	2,546	78,114	21,479	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 05 '26	Sale	30.68	1,029	31,571	19,607	Aug 06 04:14 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 03 '26	Sale	29.77	8,586	255,622	13,288	Aug 05 04:18 PM
Juvenal Tobin W	Chief Commercial Officer	Jul 31 '26	Sale	29.31	17,310	507,302	80,725	Aug 04 04:36 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 03 '26	Sale	28.25	1,730	48,872	78,995	Aug 04 04:36 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 03 '26	Option Exercise	2.39	10,664	25,487	32,143	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 31 '26	Option Exercise	2.39	6,480	15,487	27,959	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 03 '26	Sale	30.35	10,664	323,684	21,479	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 03 '26	Sale	30.35	7,829	237,634	27,009	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 31 '26	Sale	30.15	6,480	195,385	21,479	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 31 '26	Sale	30.15	3,673	110,748	30,606	Aug 04 04:35 PM
Tobin Juvenal	Chief Commercial Officer	Jul 31 '26	Proposed Sale	28.00	22,500	630,000		Jul 31 04:52 PM
Derek Maetzold	Officer	Jul 31 '26	Proposed Sale	28.00	67,662	1,894,536		Jul 31 04:52 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 27 '26	Option Exercise	2.39	6,214	14,851	27,693	Jul 29 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 27 '26	Sale	24.16	6,214	150,160	21,479	Jul 29 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 27 '26	Sale	24.16	3,622	87,523	11,812	Jul 29 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 14 '26	Option Exercise	2.39	550	1,314	22,029	Jul 16 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 14 '26	Sale	22.92	3,622	83,016	12,090	Jul 16 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 14 '26	Sale	22.92	550	12,606	21,479	Jul 16 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 01 '26	Option Exercise	2.39	6,214	14,851	27,693	Jul 06 04:25 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 01 '26	Sale	24.29	6,214	150,938	21,479	Jul 06 04:25 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 01 '26	Sale	24.29	3,622	87,978	12,368	Jul 06 04:25 PM
Oelschlager Kristen M	Chief Operating Officer	Jul 01 '26	Sale	24.42	8,586	209,650	21,874	Jul 06 04:24 PM
Derek Maetzold	Officer	Jul 01 '26	Proposed Sale	24.71	23,844	589,185		Jul 01 05:35 PM
Oelschlager Kristen M	Chief Operating Officer	Jun 16 '26	Sale	20.71	8,587	177,837	30,460	Jun 18 04:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 15 '26	Option Exercise	2.39	550	1,314	22,029	Jun 17 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 15 '26	Sale	20.66	3,622	74,831	12,646	Jun 17 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 15 '26	Sale	20.66	550	11,363	21,479	Jun 17 05:39 PM
KRISTEN OELSCHLAGER	Officer	Jun 16 '26	Proposed Sale	20.66	29,911	617,961		Jun 16 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 01 '26	Option Exercise	2.39	6,214	14,851	27,693	Jun 03 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 01 '26	Sale	20.86	6,214	129,605	21,479	Jun 03 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 01 '26	Sale	20.86	3,622	75,544	1,668	Jun 03 04:15 PM
Derek Maetzold	Officer	Jun 01 '26	Proposed Sale	20.97	14,008	293,748		Jun 01 05:39 PM
Juvenal Tobin W	Chief Commercial Officer	May 21 '26	Option Exercise	3.38	11,210	37,890	98,035	May 26 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 21 '26	Option Exercise	2.39	420	1,004	21,899	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 20 '26	Option Exercise	2.39	130	311	21,609	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 21 '26	Sale	20.20	2,763	55,802	1,946	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 20 '26	Sale	20.00	859	17,182	2,158	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 21 '26	Sale	20.20	420	8,482	21,479	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 20 '26	Sale	20.00	130	2,600	21,479	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 07 '26	Option Exercise	2.39	6,214	14,851	27,693	May 11 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 07 '26	Sale	22.15	6,214	137,663	21,479	May 11 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 07 '26	Sale	22.15	3,622	80,241	2,224	May 11 04:06 PM
Derek Maetzold	Officer	May 07 '26	Proposed Sale	19.24	14,008	269,514		May 07 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '26	Option Exercise	2.39	550	1,314	22,029	Apr 23 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '26	Sale	25.10	3,622	90,905	2,502	Apr 23 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '26	Sale	25.10	550	13,804	21,479	Apr 23 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 06 '26	Option Exercise	2.39	6,214	14,851	27,693	Apr 08 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 06 '26	Sale	25.03	6,214	155,536	21,479	Apr 08 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 06 '26	Sale	25.03	3,622	90,659	2,780	Apr 08 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Option Exercise	2.39	550	1,314	22,029	Mar 30 06:29 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Sale	25.55	3,622	92,546	3,058	Mar 30 06:29 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Sale	25.55	550	14,053	21,479	Mar 30 06:29 PM
Derek Maetzold	Officer	Mar 26 '26	Proposed Sale	24.70	18,180	449,046		Mar 26 05:36 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 17 '26	Sale	25.93	18,650	483,594	22,129	Mar 19 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 18 '26	Sale	25.39	650	16,504	21,479	Mar 19 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 16 '26	Sale	25.97	17,575	456,408	40,779	Mar 17 04:36 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 13 '26	Sale	25.45	13,204	336,002	58,354	Mar 17 04:36 PM
Juvenal Tobin W	Chief Commercial Officer	Mar 12 '26	Sale	25.24	20,863	526,582	86,825	Mar 16 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Option Exercise	2.39	6,226	14,880	112,047	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 12 '26	Sale	25.28	23,179	585,942	71,558	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Sale	26.11	17,310	451,947	94,737	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Sale	26.11	3,636	94,932	3,336	Mar 13 04:10 PM
Tobin Juvenal	Chief Commercial Officer	Mar 12 '26	Proposed Sale	25.32	20,863	528,251		Mar 12 04:38 PM
Derek Maetzold	Officer	Mar 11 '26	Proposed Sale	26.13	94,204	2,461,551		Mar 11 04:52 PM
Stokes Frank	Chief Financial Officer	Mar 05 '26	Sale	27.98	6,001	167,908	60,085	Mar 09 04:13 PM
Cole G Bradley	Director	Mar 05 '26	Option Exercise	3.38	4,748	16,048	26,712	Mar 09 04:12 PM
Cole G Bradley	Director	Mar 05 '26	Sale	28.47	7,403	210,727	19,309	Mar 09 04:12 PM
Stokes Frank	Chief Financial Officer	Mar 04 '26	Option Exercise	3.38	3,800	12,844	66,086	Mar 05 05:08 PM
Stokes Frank	Chief Financial Officer	Mar 03 '26	Sale	27.44	7,000	192,073	52,483	Mar 05 05:08 PM
FRANKLIN STOKES	Officer	Mar 05 '26	Proposed Sale	28.17	6,001	169,048		Mar 05 04:28 PM
GORDON B. COLE	Director	Mar 05 '26	Proposed Sale	28.47	7,403	210,743		Mar 05 04:04 PM
FRANKLIN STOKES	Officer	Mar 03 '26	Proposed Sale	27.99	7,000	195,930		Mar 03 04:33 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Feb 03 '26	Sale	39.91	3,200	127,722	84,515	Feb 05 04:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Feb 04 '26	Sale	37.99	817	31,035	83,698	Feb 05 04:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 20 '26	Sale	40.01	4,017	160,732	87,715	Jan 22 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 05 '26	Sale	38.09	2,678	102,005	30,852	Jan 07 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '26	Sale	40.10	1,339	53,689	29,513	Jan 07 04:06 PM
Derek Maetzold	Officer	Jan 05 '26	Proposed Sale	39.00	12,051	469,989		Jan 05 05:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 22 '25	Sale	40.35	830	33,490	33,530	Dec 29 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 17 '25	Sale	40.04	509	20,380	34,360	Dec 19 04:06 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 17 '25	Sale	39.31	14,888	585,292	12,323	Dec 19 04:06 PM
Kristen M. Oelschlager	Officer	Dec 17 '25	Proposed Sale	39.05	14,888	581,376		Dec 17 04:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '25	Sale	38.78	19,525	757,099	47,690	Dec 17 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 16 '25	Sale	38.55	12,821	494,301	34,869	Dec 17 04:20 PM
Derek Maetzold	Officer	Dec 15 '25	Proposed Sale	38.88	33,685	1,309,673		Dec 15 06:21 PM
Juvenal Tobin W	Chief Commercial Officer	Dec 11 '25	Sale	37.48	13,200	494,736	86,825	Dec 15 04:09 PM
Stokes Frank	Chief Financial Officer	Dec 11 '25	Sale	37.45	4,496	168,375	50,326	Dec 15 04:08 PM
TOBIN JUVENAL	Officer	Dec 11 '25	Proposed Sale	37.48	13,200	494,675		Dec 11 04:30 PM
FRANKLIN M. STOKES	Officer	Dec 11 '25	Proposed Sale	37.45	4,496	168,375		Dec 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '25	Sale	40.03	1,339	53,600	37,547	Dec 08 04:28 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 02 '25	Sale	39.23	2,678	105,058	38,886	Dec 04 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 26 '25	Sale	40.09	4,258	170,703	41,564	Dec 01 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 25 '25	Sale	40.05	5,115	204,851	45,822	Nov 26 02:58 PM
Derek Maetzold	Officer	Nov 25 '25	Proposed Sale	39.93	10,712	427,730		Nov 25 05:11 PM

KNSA

Kiniksa Pharmaceuticals International Plc

CSTL

Castle Biosciences Inc

Upgrade your Finviz experience